Seattle Genetics (SGEN) PT Raised to $154 at BMO Capital on Tukysa FDA Approval
Tweet Send to a Friend
BMO Capital analyst George Farmer raised the price target on Seattle Genetics (NASDAQ: SGEN) to $154.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
